<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651610</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 1401</org_study_id>
    <secondary_id>2015-003780-11</secondary_id>
    <nct_id>NCT02651610</nct_id>
  </id_info>
  <brief_title>Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this research study is to see whether adding bavituximab (an&#xD;
      investigational drug) to the standard chemotherapy drug taxane, will improve the results of&#xD;
      the treatment for HER2-negative metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label randomized trial in patients with HER2-negative metastatic breast&#xD;
      cancer. Patients will be treated with either taxane alone (investigator choice of paclitaxel&#xD;
      or docetaxel) or taxane with bavituximab. Paclitaxel will be given 3 of 4 weeks, docetaxel&#xD;
      will be given once every 3 weeks, and bavituximab will be given weekly. All therapy will&#xD;
      continue until disease progression, toxicity, withdrawal or consent, investigator decision,&#xD;
      or study termination. Efficacy (overall response rate) is the primary endpoint while safety&#xD;
      is the secondary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Measures - Adverse Events and Laboratory Evaluations</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Disease Control Rate (DCR)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Duration of Response (DOR)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall Survival</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Taxane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bavituximab plus taxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bavituximab</intervention_name>
    <description>Biological: bavituximab</description>
    <arm_group_label>Bavituximab plus taxane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxane</intervention_name>
    <description>Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol</description>
    <arm_group_label>Bavituximab plus taxane</arm_group_label>
    <arm_group_label>Taxane</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Docetaxel</other_name>
    <other_name>Docecad</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Written informed consent obtained prior to screening.&#xD;
&#xD;
          2. Females or males at least 18 years of age.&#xD;
&#xD;
          3. Histologically or cytologically documented metastatic HER2-negative breast cancer.&#xD;
&#xD;
          4. Measurable disease per RECIST 1.1 (Phase II); evaluable disease (Phase III)&#xD;
&#xD;
          5. ECOG performance status of 0 or 1.&#xD;
&#xD;
          6. Adequate hematologic function: absolute neutrophil count ≥1500 cells/µL; hemoglobin ≥9&#xD;
             g/dL; platelets ≥100,000/µL.&#xD;
&#xD;
          7. Adequate renal function: serum creatinine ≤1.8 mg/dL or calculated creatinine&#xD;
             clearance &gt;50 mL/min using the Cockcroft-Gault equation.&#xD;
&#xD;
          8. Adequate hepatic function: total bilirubin ≤ upper limit of normal (ULN), serum&#xD;
             albumin ≥3.0 g/dL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)&#xD;
             ≤1.5 × ULN. ALT and/or AST may be ≤5 × ULN if due to liver metastases. If ALT or AST&#xD;
             is &gt;1.5 and ≤5 × ULN in patients with liver metastases, alkaline phosphatase must be&#xD;
             ≤2.5 × ULN. Patients with Gilbert's syndrome are allowed if total bilirubin is ≤2 ×&#xD;
             ULN and direct bilirubin is ≤ULN.&#xD;
&#xD;
          9. Prothrombin time (PT) and/or international normalized ratio (INR) ≤1.5 × ULN and&#xD;
             activated partial thromboplastin time (aPTT) ≤1.5 × ULN if patient is not on&#xD;
             anticoagulant therapy (a therapeutic PT and/or INR and aPTT is acceptable if the&#xD;
             patient is on anticoagulants).&#xD;
&#xD;
         10. Patients must have a negative serum human chorionic gonadotropin test within 1 week of&#xD;
             Day 1 (pregnancy test not required for patients with bilateral oophorectomy and/or&#xD;
             hysterectomy or for those patients who are &gt;1 year postmenopausal).&#xD;
&#xD;
         11. All patients of reproductive potential (ie, not surgically sterile or postmenopausal)&#xD;
             must agree to use a highly effective method of contraception (&lt;1% failure rate per&#xD;
             year) during and 3 months after end of study treatment (female) or during and 6 months&#xD;
             after the end of study treatment (male).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. HER2-positive breast cancer.&#xD;
&#xD;
          2. Less than 6 months since last dose of prior adjuvant non-taxane regimen.&#xD;
&#xD;
          3. Less than 12 months since last dose of prior adjuvant taxane-containing regimen.&#xD;
&#xD;
          4. Any chemotherapy regimen for MBC within 3 weeks before Day 1.&#xD;
&#xD;
          5. Known history of bleeding diathesis or coagulopathy (eg, von Willebrand disease or&#xD;
             hemophilia).&#xD;
&#xD;
          6. Bleeding:&#xD;
&#xD;
               -  Clinically significant bleeding, such as gross hematuria, gastrointestinal&#xD;
                  bleeding, and hemoptysis within the 6 months before screening, unless the cause&#xD;
                  has been identified and adequately treated (eg, cystitis, ulcer).&#xD;
&#xD;
               -  Minor biopsy-related bleeding lasting &lt;24 hours and resolved at least 1 week&#xD;
                  before Day 1 is allowed.&#xD;
&#xD;
          7. Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial&#xD;
             thrombosis) within 6 months before screening.&#xD;
&#xD;
          8. Grade 2 or higher peripheral neuropathy (eg, numbness, tingling, and/or pain in distal&#xD;
             extremities).&#xD;
&#xD;
          9. Radiotherapy within 1 week preceding Day 1; ongoing acute toxicity from prior&#xD;
             radiotherapy.&#xD;
&#xD;
         10. Either symptomatic or clinically active brain metastases (ie, requiring ongoing&#xD;
             treatment). Patients are eligible if brain metastases are adequately treated. Patients&#xD;
             must be either off corticosteroids, or on a stable or decreasing dose of ≤10 mg daily&#xD;
             prednisone (or equivalent).&#xD;
&#xD;
         11. Major surgery within 4 weeks of Day 1.&#xD;
&#xD;
         12. Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease, active&#xD;
             infections).&#xD;
&#xD;
         13. Autoimmune disease, being treated with immunosuppressive drugs (eg, methotrexate or&#xD;
             biological agents), or other conditions requiring immunosuppressive therapy (eg, prior&#xD;
             allotransplantation).&#xD;
&#xD;
         14. History of hypersensitivity to bavituximab, docetaxel, paclitaxel, or to any of their&#xD;
             excipients.&#xD;
&#xD;
         15. Symptomatic coronary artery disease, cerebrovascular accident or transient ischemic&#xD;
             attack, myocardial infarction, arterial embolism, or unstable angina pectoris within 6&#xD;
             months of screening.&#xD;
&#xD;
         16. Currently pregnant, nursing, or planning a pregnancy during the study.&#xD;
&#xD;
         17. Investigational therapy within 28 days prior to Day 1.&#xD;
&#xD;
         18. Patient has a condition or is in a situation which, in the investigator's opinion, may&#xD;
             put the patient at significant risk, may confound the study results, or may interfere&#xD;
             significantly with the patient's participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peregrine Pharmaceuticals Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peregrine Pharmaceuticals Investigational Site</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPHM 1401</keyword>
  <keyword>bavituximab</keyword>
  <keyword>Peregrine</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>HER-2 Negative</keyword>
  <keyword>HER2 Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Bavituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

